ArticleCureus2024
Comparison of Combined Oral Contraceptives and a Transdermal Estrogen Patch With Oral Progesterone: Treatment of Abnormal Uterine Bleeding in Adolescents.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective Abnormal uterine bleeding (AUB) is a frequent complaint in adolescents. Ovulatory dysfunction (AUB-O) is the most common etiology of AUB. We aimed to compare possible treatment modalities for idiopathic AUB-O, the most common reason for AUB-O in adolescents. Methods Thirty patients who were treated with either 30 μg ethinyl estradiol/3 mg drospirenone combined oral contraceptive (group A) or 1.95 mg 17β-estradiol transdermal patch and 5 mg oral medroxyprogesterone acetate combined treatment (group B) for six months in the pediatric endocrinology department between years 2017 and 2019 were enrolled in our study retrospectively, and a questionnaire was performed on them to assess their treatment satisfaction. Results In the first three months of treatment, four (26.6%) patients reported intermenstrual bleeding (IMB), three (20%) reported abdominal pain, two (13.3%) reported nausea-vomiting, and one (6.7%) reported headaches in group A, while eight (53.3%) patients reported IMB, six (40%) reported abdominal pain, two (13.3%) reported nausea-vomiting, and two (13.3%) reported headaches in group B. No major side effects were reported to cause cessation of treatment in any treatment group, but fewer mild side effects were reported in group A. Group A had better treatment compliance and satisfaction. Menstrual irregularity stopped after two months of treatment in both groups, but one (6.6%) and three (20.0%) patients reported that AUB repeated within three months of treatment cessation in group A and group B, respectively. Conclusion Immaturity of the hypothalamo-pituitary-ovarian axis in adolescence can present with a wide range of symptoms and proves challenging to choose the proper treatment regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.